Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 6/20 | 0.61 |
| ▸ | CDK9 | P50750 | 6/20 | 0.61 |
| ▸ | CDK7 | P50613 | 6/20 | 0.61 |
| ▸ | CCNH | P51946 | 5/20 | 0.61 |
| ▸ | MNAT1 | P51948 | 5/20 | 0.61 |
| ▸ | CDK2 | P24941 | 15/20 | 0.60 |
| ▸ | MAPK8 | P45983 | 13/20 | 0.60 |
| ▸ | MAPK9 | P45984 | 13/20 | 0.60 |
| ▸ | JUN | P05412 | 12/20 | 0.60 |
| ▸ | MAPK10 | P53779 | 10/20 | 0.60 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.59 |
| ▸ | CCNK | O75909 | 2/20 | 0.59 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.59 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.59 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19024530 | 1.00 | CCNT1 (0.61) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL19054689 | 1.00 | CCNT1 (0.61) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL19024595 | 0.90 | CDK2 (0.62) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL20416185 | 0.90 | CCNT1 (0.62) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL17150723 | 0.90 | CDK2 (0.62) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL17141285 | 0.89 | MAPK8 (0.69) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL19054697 | 0.88 | CDK2 (0.72) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL19054696 | 0.88 | CDK2 (0.72) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL19054682 | 0.88 | CDK2 (0.61) | CCNT1CDK9CDK7CCNHMNAT1 | |
| SCHEMBL19024598 | 0.88 | CDK2 (0.61) | CCNT1CDK9CDK7CCNHMNAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3489232-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2019-05-29 | — | — | EP | disclosed |
| EP-3489232-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20180319772-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-11-08 | — | — | US | disclosed |
| US-10106526-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| US-10059690-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2018-08-28 | — | — | US | disclosed |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-07-26 | — | — | US | disclosed |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-07-26 | — | — | US | disclosed |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-07-26 | — | — | US | disclosed |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-06-29 | — | — | US | disclosed |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-06-29 | — | — | US | disclosed |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-06-29 | — | — | US | disclosed |
| WO-2015154039-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10059690-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | CCNT1 34/4885CDK9 3/4885CDK7 1/4885 |
| US-10106526-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | CCNT1 34/4885CDK9 3/4885CDK7 1/4885 |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CCNT1 34/4885CDK9 3/4885CDK7 1/4885 |
| US-20180319772-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CCNT1 34/4885CDK9 3/4885CDK7 1/4885 |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CCNT1 34/4885CDK9 3/4885CDK7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.